JQ1 targeting BRD4 enhances cisplatin-induced pyroptosis via LDHA-mediated ROS release to potentially overcome chemoresistance in bladder cancer.
Cisplatin-based chemotherapy is a cornerstone treatment for muscle-invasive bladder cancer (MIBC), yet resistance to cisplatin and its adverse effects limit clinical efficacy. Novel strategies to sensitize tumors to cisplatin are urgently needed. As a chromatin reading protein, BRD4 can regulate gene expression and pla...